567 related articles for article (PubMed ID: 28660366)
1. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
3. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring.
Melilli E; Crespo E; Sandoval D; Manonelles A; Sala N; Mast R; Padulles A; Grinyo JM; Bestard O; Cruzado JM
Transpl Int; 2015 Nov; 28(11):1283-90. PubMed ID: 26088437
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
Spence MM; Nguyen LM; Hui RL; Chan J
Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
[TBL] [Abstract][Full Text] [Related]
5. Converting immunosuppression from an oral suspension to a granule formulation of tacrolimus in pediatric renal transplant recipients.
Malakasioti G; Booth C; Marks SD
Pediatr Transplant; 2018 Aug; 22(5):e13214. PubMed ID: 29767471
[TBL] [Abstract][Full Text] [Related]
6. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients.
Lichvar A; Tremblay S; Naik D; Lipscomb J; King E; Vinks AA; Christians U; Alloway RR
Pharmacotherapy; 2019 May; 39(5):564-575. PubMed ID: 30892704
[TBL] [Abstract][Full Text] [Related]
8. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function.
Momper JD; Ridenour TA; Schonder KS; Shapiro R; Humar A; Venkataramanan R
Am J Transplant; 2011 Sep; 11(9):1861-7. PubMed ID: 21714845
[TBL] [Abstract][Full Text] [Related]
9. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
[TBL] [Abstract][Full Text] [Related]
10. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
[TBL] [Abstract][Full Text] [Related]
11. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients.
Heavner MS; Tichy EM; Yazdi M; Formica RN; Kulkarni S; Emre S
Am J Health Syst Pharm; 2013 Sep; 70(17):1507-12. PubMed ID: 23943182
[TBL] [Abstract][Full Text] [Related]
13. Systematic conversion to generic tacrolimus in stable kidney transplant recipients.
Rosenborg S; Nordström A; Almquist T; Wennberg L; Bárány P
Clin Kidney J; 2014 Apr; 7(2):151-155. PubMed ID: 24944783
[TBL] [Abstract][Full Text] [Related]
14. Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication.
Abdulnour HA; Araya CE; Dharnidharka VR
Pediatr Transplant; 2010 Dec; 14(8):1007-11. PubMed ID: 20819180
[TBL] [Abstract][Full Text] [Related]
15. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
[TBL] [Abstract][Full Text] [Related]
16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
17. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
18. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
[TBL] [Abstract][Full Text] [Related]
20. STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany.
Lehner LJ; Kalb K; Weigand K; Pein U; Schenker P; Seeger W; Roehle R; Dienes K; Halleck F; Budde K
Curr Rev Clin Exp Pharmacol; 2021; 16(4):357-368. PubMed ID: 33588739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
